Huashan Hospital: Tuberculosis trials

The registry lists 17 Tuberculosis studies with Huashan Hospital as lead sponsor. 5 are open to participants now and 0 have results posted.

Phase 2 1Phase 3 5Phase 4 2No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Artificial Intelligence-driven Tuberculosis Landscape Analysis & Stratification ResearchNot yet recruitingNCT07611695
• Asymptomatic TB With Innovative Modified Short-course RegimensRecruitingNCT06153069Phase 4
• Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis PatientsRecruitingNCT06033807
• A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)RecruitingNCT06022146Phase 3
• Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)RecruitingNCT05401071Phase 2/3
• The Prevalence and Reproductive Outcome of Infertile Women With Genital TuberculosisStatus unknownNCT05311423
• Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUSCompletedNCT04717908Not applicable
• Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital TuberculosisStatus unknownNCT04528277Phase 3
• MDR-TB Close Contacts Tracing in China (TCCT Study)Status unknownNCT04484129
• Delayed Diagnosis of Bacteriologically Positive Pulmonary Tuberculosis and Relative Optimized Suggestions in ChinaCompletedNCT04434976
• Evaluation of CRISPR-based Test for the Rapid Identification of TB in Pulmonary Tuberculosis SuspectsStatus unknownNCT04074369
• Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)Status unknownNCT03900858Not applicable
• Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous MeningitisStatus unknownNCT03898635
• Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)CompletedNCT03867136Phase 4
• NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TBStatus unknownNCT03604848Not applicable
• Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis PreventionCompletedNCT02430259Phase 3
• Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of PyrazinamideStatus unknownNCT02120638Phase 3